U.S. Coronary Artery Bypass Graft Market Size, Share & Forecast 2026–2032

ID: MR-11674 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: U.S. Coronary Artery Bypass Graft Market
  • ✓Market Size 2024: USD 2.14 billion
  • ✓Market Size 2032: USD 3.00 billion
  • ✓CAGR: 4.3%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Endoscopic Harvesting Expansion: Medtronic's Endoscopic Vessel Harvesting system remains the reference platform, yet community hospitals across the South still rely on open saphenous vein harvest. Disposable endoscopes shift recurring consumable revenue per case, making harvesting technique a direct driver of supplier share.
FINDING 02
Contrarian PCI Resilience: The assumption that PCI growth will erode CABG volumes misreads the market. The 2021 ACC/AHA revascularization guideline keeps CABG as the preferred option for diabetic multivessel disease, so surgical volumes and consumables stay resilient through 2032 despite stent expansion.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Hospital Contracts Early: Device entrants should secure FDA 510(k) clearance and a Vizient or Premier contract listing by Q3 2026, targeting high-volume academic cardiac programs before TEAM episode pricing tightens hospital supply budgets. Early placement locks multi-year procurement and generates STS-benchmarked outcomes data.

Coronary Artery Bypass Grafting in the U.S.: Market Overview

The U.S. coronary artery bypass graft market is structurally distinct from the global norm because it centers on a single high-acuity procedure performed roughly 200,000 times annually across more than 1,000 hospitals with on-site cardiac surgery programs. Revenue flows from vein harvesting systems, synthetic conduits, cardiopulmonary bypass circuits, anastomotic devices, and cell salvage consumables. Medicare funds the majority of CABG volume, so reimbursement design shapes product adoption as much as clinical performance. Procedure volume concentrates in tertiary academic centers, which set purchasing standards for surrounding community hospitals.

The market was valued at USD 2.14 billion in 2024, with procurement decided by hospital value analysis committees rather than individual surgeons. Off-pump and minimally invasive techniques have moved spend toward disposable stabilizers and endoscopic instruments, while Vizient and Premier group contracts compress unit prices on commodity consumables. Compared with the global market, the U.S. is mature and price-disciplined, where clinical differentiation must be proven through outcomes data in the STS National Database.

Growth Drivers in U.S. Coronary Artery Bypass Grafting

Demand rests on demographics first. More than 20 million American adults live with coronary artery disease, and the population aged 65 and older will keep expanding through 2032 as baby boomers reach peak revascularization ages. The 2021 ACC/AHA Guideline for Coronary Artery Revascularization favors CABG over PCI for many patients with diabetes and multivessel disease, protecting surgical share as stenting grows. CDC-tracked diabetes prevalence adds directly to this eligible patient pool.

Second, technology adoption raises spend per case. Endoscopic vein harvesting, off-pump cardiac stabilizers, and mini-thoracotomy approaches each add disposables, while STS Adult Cardiac Surgery Database benchmarking rewards programs that reduce complications, encouraging premium device uptake. Third, CMS's Transforming Episode Accountability Model, which includes CABG episodes from January 2026, rewards lower-cost, lower-complication surgery, pushing hospitals toward proven, evidence-backed consumables.

Market Restraints and Entry Barriers

Regulatory entry is slowed by FDA premarket requirements. Most vein harvesting devices, graft conduits and anastomotic connectors clear through 510(k) substantial equivalence review under 21 CFR 870.3450 for vascular graft prostheses, but novel synthetic conduits require premarket approval. Hospitals also demand STS registry evidence before adopting new consumables, extending evaluation cycles to 12 to 18 months. Clinical champions must document outcomes before value analysis committees approve any substitution.

Commercial access is constrained by group purchasing and incumbent integration. Vizient and Premier contracts lock pricing for multi-year terms, and Medtronic, Getinge and Terumo bundle perfusion circuits with service agreements that make standalone entry costly. New York and New Jersey still require certificate-of-need approval for open-heart surgery programs, limiting new customer sites, while TEAM episode pricing squeezes hospital supply budgets. Entrants must therefore win through existing cardiac surgery accounts rather than greenfield hospital programs.

Market Opportunities in the United States

The clearest near-term opportunity is endoscopic vein harvesting outside academic centers. Community hospitals account for a large share of U.S. CABG programs but adopt endoscopic systems more slowly, and an estimated USD 280 million consumables pool sits within current procedure volumes at today's per-case pricing. Vendors offering bundled training, disposable endoscopes and STS-linked outcomes reporting can capture this gap before TEAM pressure intensifies. Each converted case adds recurring revenue without requiring new capital equipment.

A second opportunity sits in regional hub-and-spoke partnerships, where rural hospitals refer surgical patients to tertiary programs under TEAM-related care coordination. Suppliers that integrate graft tracking, inventory consolidation and post-discharge monitoring into these networks can secure multi-year volume commitments. Under the CMS Transitional Coverage for Emerging Technologies pathway, breakthrough conduits with strong evidence can obtain coverage faster, supporting premium pricing for next-generation grafts. Medicare-eligible patients drive most of this volume.

Market at a Glance

MetricValue
Market Size 2024USD 2.14 billion
Market Size 2032USD 3.00 billion
Growth Rate (CAGR)4.3%
Most Critical Decision FactorHospital value analysis committee and GPO contract access
Largest RegionSouth (Census Region)
Competitive StructureConsolidated oligopoly with GPO-driven price competition

Leading Market Participants

  • Medtronic
  • Getinge
  • Terumo Cardiovascular
  • LivaNova
  • LeMaitre Vascular
  • W. L. Gore & Associates
  • Johnson & Johnson MedTech
  • Abbott
  • Haemonetics
  • Edwards Lifesciences

Regulatory and Policy Environment

The Food and Drug Administration regulates CABG devices under 21 CFR Part 870 cardiovascular regulations, with 510(k) decisions targeting 90 FDA review days and premarket approvals requiring clinical trial data. Manufacturers must maintain quality system compliance under 21 CFR Part 820 and report adverse events through the Medical Device Reporting program. The Centers for Medicare and Medicaid Services sets hospital payment through the annual Inpatient Prospective Payment System final rule, which assigns CABG cases to MS-DRGs 233 through 236, with final rules published each August and effective October 1.

Policy and research funding shape the pipeline. The National Heart, Lung, and Blood Institute budget exceeds USD 4 billion annually, funding graft patency and tissue engineering research. Under TEAM, which begins in January 2026, hospitals face episode-based payment accountability across 90 days post-discharge, while the CMS Transitional Coverage for Emerging Technologies pathway provides expedited coverage for breakthrough devices. State certificate-of-need laws add a further compliance layer for new program entry.

Long-Term Outlook for CABG in the United States

By 2032, the U.S. CABG market will approach USD 3.00 billion, driven primarily by aging coronary disease populations and steady consumables attachment rates rather than procedure volume growth. Endoscopic harvesting and off-pump approaches will dominate new device spend, while synthetic conduit adoption stays limited to revision and small-vessel cases. Competitive intensity will rise as Medtronic, Getinge and Terumo defend installed perfusion bases against focused harvesting specialists.

Pricing pressure will define the period. TEAM episode accountability and GPO consolidation will compress unit prices on commodity grafts, pushing suppliers toward outcomes-based contracts and bundled service agreements. Hospitals that document lower complication rates in the STS database will gain procurement preference, making registry performance a commercial asset. Entrants that secure FDA clearance and GPO placement before 2028 will hold the strongest positions by 2032.

Frequently Asked Questions

Target Vizient and Premier contract listings first, since value analysis committees rarely approve off-contract consumables. Secure STS-linked outcomes data before pitching cardiac surgeons.
Most vein harvesting devices, conduits and anastomotic connectors clear through 510(k) under vascular graft prosthesis classifications. Novel synthetic conduits typically require premarket approval supported by clinical trial data.
Yes, in states including New York and New Jersey, new open-heart surgery programs require state approval. Entrants should prioritize existing cardiac surgery programs in states without these restrictions.
TEAM applies episode-based accountability to CABG cases from January 2026, pushing hospitals to reduce supply costs. Suppliers should package consumables with outcomes evidence to justify premium pricing.
Endoscopic vein harvesting consumables in community hospitals offer the clearest near-term growth. Each converted case adds recurring disposable revenue without requiring capital equipment.

Market Segmentation

By Product Type
  • Saphenous Vein Harvesting Systems
  • Synthetic Vascular Grafts
  • Cardiopulmonary Bypass Systems
  • Anastomotic Devices
  • Cell Salvage Systems
By Procedure Approach
  • On-Pump CABG
  • Off-Pump CABG
  • Minimally Invasive CABG
  • Hybrid Revascularization
By End User
  • Academic Medical Centers
  • Community Hospitals
  • Veterans Affairs Hospitals
  • Specialty Cardiac Hospitals

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. CABG Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Saphenous Vein Harvesting Systems
4.2 Synthetic Vascular Grafts
4.3 Cardiopulmonary Bypass Systems
4.4 Anastomotic Devices
4.5 Others
Chapter 05 Procedure Approach Insights
5.1 On-Pump CABG
5.2 Off-Pump CABG
5.3 Minimally Invasive CABG
5.4 Hybrid Revascularization
5.5 Others
Chapter 06 End User Insights
6.1 Academic Medical Centers
6.2 Community Hospitals
6.3 Veterans Affairs Hospitals
6.4 Specialty Cardiac Hospitals
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Medtronic
7.2.2 Getinge
7.2.3 Terumo Cardiovascular
7.2.4 LivaNova
7.2.5 LeMaitre Vascular
7.2.6 W. L. Gore & Associates
7.2.7 Johnson & Johnson MedTech
7.2.8 Abbott
7.2.9 Haemonetics
7.2.10 Edwards Lifesciences
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.